Aduro buries an­oth­er can­cer vac­cine af­ter CRS-207 joins the line­up of clin­i­cal dis­as­ters

Af­ter stick­ing it out through a par­tial hold and ear­li­er clin­i­cal tri­al set­backs, Aduro $ADRO is fi­nal­ly wash­ing its hands of a can­cer vac­cine that rep­re­sent­ed its most ad­vanced clin­i­cal pro­gram.

About 18 months af­ter a com­bi­na­tion of GVAX and CRS-207 missed the mark on pan­cre­at­ic can­cer, com­pared to chemo, the Berke­ley, CA-based biotech is throw­ing in the tri­al on CRS-207, which the biotech had held on to in or­der to pur­sue some clin­i­cal ev­i­dence of ef­fi­ca­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.